Fujirebio Multiplex Ovarian Cancer Assay Development Will Take 1-2 Years
This article was originally published in The Gray Sheet
Executive Summary
Fujirebio Diagnostics plans to develop a multiplex assay for early detection of ovarian cancer that combines mesothelin and HE4 markers with the firm's CA 125 II serum-based assay
You may also be interested in...
Fujirebio Diagnostics CA 19-9
First blood test for monitoring pancreatic cancer gains FDA market clearance, announced May 13. The laboratory radioimmunoassay accurately tracks response to chemotherapy treatment and disease status, the Malvern, Pennsylvania company claims. The assay will be distributed exclusively by Polymedco...
Bion Debuts First Rx At-Home Tumor Marker Assay For Bladder Cancer
Bion Diagnostic Sciences' BTA stat tumor marker assay for bladder cancer, the first such test to enter the prescription at-home market, is expected to be available in mid-February following FDA clearance Dec. 17.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.